The culmination of a six year study led by cardiologists at Duke University showcased the phenomenal benefits of cholesterol lowering agents Ezetimibe and Simvastatin, also known as the brand name drug Vytorin. Study results were conclusive in determining the importance of low LDL levels of cholesterol, with ultra-low levels being ideal. Not only does lowering LDL levels with the combination duo of Ezetimibe and Simvastatin prevent inflammation, it also significantly lowers heart attack risk. The data from this landmark study was presented at an American Heart Association meeting at the end of November 2014, which revealed a sizable number of clinical trial participants, roughly 18,000 adults. The adults enrolled in the six year study had either suffered a heart attack or severe chest pain requiring hospitalization. Patients received the statin Simvastatin or a combination statin (Ezetimibe and Simvastatin) in this random trial. While both groups of participants gleaned lowered LDL cholesterol levels, the patient population who received the duo of Ezetimibe and Simvastatin (Vytorin) gained the greatest benefit physically.
Patients who were administered Simvastatin alone experienced an average LDL level of 69, which is one point lower than the target level for high risk patients that many cardiologists seek. The participants who received the combination of Simvastatin and Ezetimibe saw an average of 54 for their LDL levels- far lower than experts imagined they could elicit. The question remained for study analysts if these extremely low levels of LDL could actually be harmful to the patients. However, long term results of very low LDL levels happily surprised researchers in this study. Those patients who took the powerful combination drug Vytorin experienced a 6.4 percent reduction in cardiac events, including heart disease deaths, initial or subsequent heart attacks and strokes. Additionally, patients who were administered the Simvastatin/Ezetimibe drug experienced a major reduction in hospitalizations, bypass surgeries and stent procedures. Statistically, the take away reveals that approximately two out of every one hundred patients avoids a heart attack or stroke by taking the Simvastatin and Ezetimibe combination. Further positive news emerged from this study indicating no increased risk of negative adverse effects occurred from the use of these drugs together. Side effects may occur for some patients, which could include headache, diarrhea and muscle aches. The effectiveness of Simvastatin and Ezetimibe is proven, with this omnipotent medication working by preventing the production of LDL and keeping cholesterol from absorption in the gut.
The drug Vytorin, which is marketed by Merck, will be available as a generic product in 2016. LGM Pharma can assist clients as a supplier/distributor of the TEVA APIs Ezetimibe, CAS # 163222-33-1 and Simvastatin, CAS # 79902-63-9 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.